Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective
Key Highlights
- ➤SEC declared Chemomab’s S-4 registration statement effective October 30, 2026
- ➤Chemomab shareholders vote December 4, 2026, on the proposed Scipher merger
- ➤Combined company expected to trade on Nasdaq under ticker SCIP
- ➤Scipher holders expected to own 68% of the combined company; Chemomab holders 32%
- ➤Nebokitug rheumatoid arthritis Phase 2 trial expected to start first half 2027
Special meeting of Chemomab shareholders to vote on the proposed merger scheduled for December 4, 2026
TEL AVIV, Israel, and DURHAM, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics (Nasdaq: CMMB) (“Chemomab”) and Scipher Medicine Corporation (“Scipher”), a leader in immunology precision medicine, today announced that on October 30, 2026, the U.S. Securities and Exchange Commission (“SEC”) declared effective the Registration Statement on Form S-4 (as amended, the “Registration Statement”) filed by Chemomab and Snowdrift Parent Corporation in connection with the previously announced proposed business combination between Chemomab and Scipher. The definitive proxy statement/prospectus for the special meeting of Chemomab’s shareholders in connection with the proposed merger (the “Proxy Statement”) is now also available.
Get started
Create a free account to read the full story.